{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T13:54:42Z","timestamp":1788184482543,"version":"build-2803163510"},"reference-count":23,"publisher":"Georg Thieme Verlag KG","issue":"02","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Nucl Med"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Objective\u2003The incidence of inoperable hepatocellular carcinoma (HCC) with\/without malignant portal vein thrombosis (PVT) is increasing in India for the last decade; thus, Bhabha Atomic Research Centre (BARC), Mumbai, India, developed diethydithiocarbamate (DEDC), a new transarterial radionuclide therapy (TART) agent. 188Re-N-DEDC lipiodol is an emerging radiotherapeutic agent for inoperable HCC treatment due to its simple and onsite labeling procedure, cost-effectiveness, and least radiation-induced side effects. This study aimed to evaluate in-vivo biodistribution and clinical feasibility of 188Re-N-DEDC lipiodol TART in HCC and optimization of labeling procedure to assess post-labeling stability and radiochemical yield of labeled lipiodol with 188Re-N-DEDC complex.<\/jats:p>\n                  <jats:p>Materials and Methods\u2003DEDC kits were obtained as gift from BARC, Mumbai. Therapy was given to 31 HCC patients. Post-therapy planar and single-photon emission computed tomography\/computed tomography (SPECT\/CT) imaging were performed to see tumor uptake and biodistribution. Clinical feasibility and toxicity were decided by Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v 5.0).<\/jats:p>\n                  <jats:p>Statistical Analysis\u2003Descriptive statistics was done for data using SPSS v22. Values was expressed as mean\u2009\u00b1\u2009standard deviation or median with range.<\/jats:p>\n                  <jats:p>Results\u2003Post-therapy planar and SPECT\/CT imaging showed radiotracer localization in hepatic lesions. Few patients showed lungs uptake due to hepato-pulmonary shunt (lung shunt\u2009&lt;\u200910%). Maximum clearance was observed through urinary tract with very less elimination through hepatobiliary route due to slow rate of leaching of tracer. No patient showed myelosuppression or any other long-term toxicity over median follow-up of 6 months. Mean overall % radiochemical yield of 188Re-N-DEDC lipiodol was 86.04\u2009\u00b1\u20092.35%. The complex 188Re-N-DEDC was found to be stable at 37\u00b0C under sterile condition over a period of 1\u2009hour without any significant change on the % radiochemical purity (90.83\u2009\u00b1\u20093.24%, 89.78\u2009\u00b1\u20093.67%, 89.22\u2009\u00b1\u20093.77% at 0, 0.5, 1\u2009hours, respectively).<\/jats:p>\n                  <jats:p>Conclusion\u2003Human biodistribution showed very high retention of radiotracer in hepatic lesions with no long-term toxicity with this therapy. The kit preparation procedure is ideally suited for a busy hospital radio-pharmacy. By this procedure, 188Re-N-DEDC lipiodol can be prepared in high radiochemical yield within a short time (\u223c45\u2009minutes). Thus, 188Re-N-DEDC lipiodol can be considered for TART in advanced and\/or intermediate HCC.<\/jats:p>","DOI":"10.1055\/s-0043-1764306","type":"journal-article","created":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T18:48:15Z","timestamp":1682966895000},"page":"114-123","source":"Crossref","is-referenced-by-count":4,"title":["188Re-N-DEDC Lipiodol for Treatment of Hepatocellular Carcinoma (HCC)\u2014A Clinical and Prospective Study to Assess In-Vivo Distribution in Patients and Clinical Feasibility of Therapy"],"prefix":"10.1055","volume":"22","author":[{"given":"Naresh","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, All India Institute of Medical Sciences (AIIMS), New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, All India Institute of Medical Sciences (AIIMS), New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamim Ahmed","family":"Shamim","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, All India Institute of Medical Sciences (AIIMS), New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7073-7348","authenticated-orcid":false,"given":"Viju","family":"Chirayil","sequence":"additional","affiliation":[{"name":"Bhabha Atomic Research Centre, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5895-7265","authenticated-orcid":false,"given":"Suresh","family":"Subramanian","sequence":"additional","affiliation":[{"name":"Bhabha Atomic Research Centre, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhava B.","family":"Mallia","sequence":"additional","affiliation":[{"name":"Bhabha Atomic Research Centre, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandrasekhar","family":"Bal","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, All India Institute of Medical Sciences (AIIMS), New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2023,5,1]]},"reference":[{"issue":"06","key":"ref1","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1586\/17474124.2015.1028363","article-title":"The evolving epidemiology of hepatocellular carcinoma: a global perspective","volume":"9","author":"M C Wallace","year":"2015","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"06","key":"ref2","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1046\/j.1440-1746.2001.02476.x","article-title":"Profile of hepatocellular carcinoma in India: an insight into the possible etiologic associations","volume":"16","author":"S K Sarin","year":"2001","journal-title":"J Gastroenterol Hepatol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000231886","article-title":"Clinical profile, etiology and therapeutic outcome in 324 hepatocellular carcinoma patients at a tertiary care center in India","volume":"77","author":"S B Paul","year":"2009","journal-title":"Oncology"},{"issue":"03","key":"ref4","first-page":"311","article-title":"World Gastroenterology Organisation Guideline. Hepatocellular carcinoma (HCC): a global perspective","volume":"19","author":"P Ferenci","year":"2010","journal-title":"J Gastrointestin Liver Dis"},{"issue":"12","key":"ref5","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1001\/jamaoncol.2017.3055","article-title":"The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: results from the Global Burden of Disease Study 2015","volume":"3","author":"T Akinyemiju","year":"2017","journal-title":"JAMA Oncol"},{"issue":"02","key":"ref6","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/hep.29498","article-title":"Projections of primary liver cancer to 2030 in 30 countries worldwide","volume":"67","author":"P C Valery","year":"2018","journal-title":"Hepatology"},{"issue":"04","key":"ref7","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.jhep.2012.11.045","article-title":"Heavy alcohol consumption increases the incidence of hepatocellular carcinoma in hepatitis B virus-related cirrhosis","volume":"58","author":"C W Lin","year":"2013","journal-title":"J Hepatol"},{"issue":"03","key":"ref8","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1055\/s-2007-1007122","article-title":"Prognosis of hepatocellular carcinoma: the BCLC staging classification","volume":"19","author":"J M Llovet","year":"1999","journal-title":"Semin Liver Dis"},{"issue":"01","key":"ref9","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jhep.2003.09.027","article-title":"The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available?","volume":"40","author":"U Cillo","year":"2004","journal-title":"J Hepatol"},{"issue":"04","key":"ref10","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/j.transproceed.2009.03.054","article-title":"Validation of the BCLC prognostic system in surgical hepatocellular cancer patients","volume":"41","author":"A Vitale","year":"2009","journal-title":"Transplant Proc"},{"issue":"04","key":"ref11","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"J M Llovet","year":"2008","journal-title":"N Engl J Med"},{"issue":"01","key":"ref12","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"A L Cheng","year":"2009","journal-title":"Lancet Oncol"},{"issue":"04","key":"ref13","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/hep.29691","article-title":"Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience","volume":"68","author":"R Salem","year":"2018","journal-title":"Hepatology"},{"issue":"06","key":"ref14","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1378\/chest.10-1591","article-title":"131I-labeled lipiodol-induced interstitial pneumonia: a series of 15 cases","volume":"139","author":"S Jouneau","year":"2011","journal-title":"Chest"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"132","DOI":"10.3389\/fmed.2019.00132","article-title":"Rhenium-188 labeled radiopharmaceuticals: current clinical applications in oncology and promising perspectives","volume":"6","author":"N Lepareur","year":"2019","journal-title":"Front Med (Lausanne)"},{"issue":"01","key":"ref16","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.apradiso.2006.07.008","article-title":"Development of acetylated HDD kit for preparation of 188Re-HDD\/lipiodol","volume":"65","author":"Y S Lee","year":"2007","journal-title":"Appl Radiat Isot"},{"issue":"12","key":"ref17","first-page":"2033","article-title":"Lipiodol solution of 188Re-HDD as a new therapeutic agent for transhepatic arterial embolization in liver cancer: preclinical study in a rabbit liver cancer model","volume":"44","author":"J C Paeng","year":"2003","journal-title":"J Nucl Med"},{"issue":"07","key":"ref18","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1097\/01.mnm.0000130241.22068.45","article-title":"A kit formulation for the preparation of 188Re-lipiodol: preclinical studies and preliminary therapeutic evaluation in patients with unresectable hepatocellular carcinoma","volume":"25","author":"A Boschi","year":"2004","journal-title":"Nucl Med Commun"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.apradiso.2018.03.018","article-title":"Improved freeze-dried kit for the preparation of 188ReN-DEDC\/lipiodol for the therapy of unresectable hepatocellular carcinoma","volume":"137","author":"M B Mallia","year":"2018","journal-title":"Appl Radiat Isot"},{"issue":"04","key":"ref20","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/0883-2897(86)90027-9","article-title":"The chemistry of rhenium and technetium as related to the use of isotopes of these elements in therapeutic and diagnostic nuclear medicine","volume":"13","author":"E Deutsch","year":"1986","journal-title":"Int J Rad Appl Instrum B"},{"issue":"04","key":"ref21","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0969-8051(03)00002-7","article-title":"High-yield synthesis of the terminal 188Re triple bond N multiple bond from generator-produced [188ReO4](-)","volume":"30","author":"A Boschi","year":"2003","journal-title":"Nucl Med Biol"},{"issue":"01","key":"ref22","first-page":"63","article-title":"Preparation of rhenium-188-lipiodol using freeze-dried kits for transarterial radioembolization: an overview and experience in a hospital radiopharmacy","volume":"37","author":"E R Radhakrishnan","year":"2022","journal-title":"Cancer Biother Radiopharm"},{"issue":"01","key":"ref23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/ijnm.IJNM_133_17","article-title":"Radiation dose to the occupational worker during the synthesis of 188Re-labeled Radiopharmaceuticals in the Nuclear Medicine Department","volume":"33","author":"P Thakral","year":"2018","journal-title":"Indian J Nucl Med"}],"container-title":["World Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0043-1764306.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T12:44:00Z","timestamp":1764161040000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0043-1764306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,1]]},"references-count":23,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2023,5,22]]},"published-print":{"date-parts":[[2023,6]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0043-1764306","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["1450-1147","1607-3312"],"issn-type":[{"value":"1450-1147","type":"print"},{"value":"1607-3312","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,1]]}}}